Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (CC): Updated analysis of stage II disease from the AVANT phase III randomized trial by the GERCOR group

被引：0
|
作者：
De Gramont, A. [1 ]
Henriques, J. [2 ]
Baruch, B. [3 ,4 ]
Kim, T. W. [5 ]
Martinez-Villacampa, M. [6 ]
Gallego-Plazas, J. [7 ]
Cervantes, A. [8 ]
Shim, K. [9 ]
Jonker, D. J. [10 ]
Guerin-Meyer, V. [11 ]
Mineur, L. [12 ]
Banzi, M. [13 ]
Dewdney, A. [14 ]
Dejthevaporn, T. Sirisingha [15 ]
Bloemendal, H. J. [16 ]
Roth, A. D. [17 ]
Thompson, P. [18 ]
Moehler, M. [19 ]
Aranda Aguilar, E. [20 ]
Andre, T. [21 ]
机构：
[1] Inst Hosp Franco Britannique, Dept Med Oncol, Levallois Perret, France
[2] Univ Hosp Besancon, INSERM, UMR 1098, Methodol & Qual Life Unit Oncol, Besancon, France
[3] Rabin Med Ctr, Davidoff Canc Ctr, Dept Oncol, Petah Tiqwa, Israel
[4] Sackler Sch Med, Tel Aviv, Israel
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[6] Inst Catala Oncol IDIBELL Hospitalet, Dept Med Oncol, Barcelona, Spain
[7] Gen Univ Elche Hosp, Dept Med Oncol, Elche, Spain
[8] Hosp Clin Univ Valencia, Med Oncol, Valencia, Spain
[9] Lakeridge Hlth RS McLaughlin Durham Reg Canc Ctr, Med Oncol, Oshawa, ON, Canada
[10] Univ Ottawa, Ottawa Hosp Res Inst, Div Med Oncol, Dept Med, Ottawa, ON, Canada
[11] Inst Cancerol Ouest Paul Papin, Dept Gastroenterol & Hepatol, Angers, France
[12] Inst St Catherine, Radiotherapy & Oncol GI & Liver, Avignon, France
[13] Azienda Osped Arcispedale Santa Maria Nuova IRCCS, Oncol Unit, Reggio Emilia, Italy
[14] Weston Pk Hosp, Canc Res Ctr, Dept Oncol, Sheffield, S Yorkshire, England
[15] Ramathibodi Hosp, Med Oncol, Bangkok, Thailand
[16] Meander Med Ctr, Dept Internal Med Med Oncol, Amersfoort, Netherlands
[17] HUG, Dept Oncol, Digest Tumour Unit, Geneva, Switzerland
[18] Auckland City Hosp, Dept Med Oncol, Auckland, New Zealand
[19] Univ Med Mainz, Dept Med Oncol, Mainz, Germany
[20] Univ Hosp Reina Sofia, Dept Med Oncol, Cordoba, Spain
[21] Hop St Antoine, Dept Med Oncol, Paris, France
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
553P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study)
    Nakayama, Goro
    Takano, Nao
    Taniguchi, Hiroya
    Ishigure, Kiyoshi
    Yokoyama, Hiroyuki
    Teramoto, Hitoshi
    Hashimoto, Ryoji
    Sakai, Mitsuru
    Ishiyama, Akiharu
    Kinoshita, Takashi
    Hayashi, Naomi
    Nakamura, Masanori
    Hattori, Norifumi
    Sato, Yusuke
    Umeda, Shinichi
    Uehara, Kei
    Aiba, Toshisada
    Sonohara, Fuminori
    Hayashi, Masamichi
    Kanda, Mitsuro
    Kobayashi, Daisuke
    Tanaka, Chie
    Yamada, Suguru
    Koike, Masahiko
    Fujiwara, Michitaka
    Murotani, Kenta
    Ando, Masahiko
    Ando, Yuichi
    Muro, Kei
    Kodera, Yasuhiro
    EUROPEAN JOURNAL OF CANCER, 2021, 144 : 61 - 71
  • [22] PHARMACOGENETIC PREDICTORS OF SEVERE CHRONIC PERIPHERAL NEUROPATHY IN STAGE II-III COLON CANCER (CC) PATIENTS TREATED WITH OXALIPLATIN-BASED ADJUVANT CHEMOTHERAPY (CT). A GEMCAD STUDY
    Custodio, A.
    Moreno, J.
    Aparicio, J.
    Gallego Plazas, J.
    Fernandez Martos, C.
    Maurel, J.
    Ramos, D.
    Cejas, P.
    Madero, R.
    Feliu, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 181 - 181
  • [23] Cancer stem cells profile and clinical outcome in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy
    Giampieri, Riccardo
    Scartozzi, Mario
    Loretelli, Cristian
    Del Prete, Michela
    Faloppi, Luca
    Bianconi, Maristella
    Bittoni, Alessandro
    Mandolesi, Alessandra
    Bearzi, Italo
    Cascinu, Stefano
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [24] LEANOX: Lean body mass normalization of oxaliplatin-based chemotherapy for patients with stage III colon cancer treated in adjuvant setting: Impact on oxaliplatin-induced sensitive neurotoxicity-A multicenter phase II randomized trial.
    Assenat, Eric
    Ben Abdelghani, Meher
    Monnier, Maeva
    Perrier, Herve
    Khemissa, Faiza
    Desgrippes, Romain
    Galais, Marie-Pierre
    Rinaldi, Yves
    Lepage, Come
    Tetreau, Raphael
    Senesse, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 92 - 92
  • [25] S-1 as adjuvant chemotherapy for stage III colon cancer: Updated outcomes of ACTS-CC trial
    Kinugasa, Yusuke
    Ishiguro, Megumi
    Nakatani, Eiji
    Endo, Takeshi
    Shinozaki, Hiroharu
    Takii, Yasumasa
    Takahashi, Yu
    Mochizuki, Hidetaka
    Kotake, Kenjiro
    Kameoka, Shingo
    Takahashi, Keiichi
    Watanabe, Toshiaki
    Watanabe, Masahiko
    Boku, Narikazu
    Tomita, Naohiro
    Sugihara, Kenichi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] Baseline creatinine clearance as an indicator of severe adverse events associated with oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer: Safety analysis of the phase III Japanese ACHIEVE trial
    Nakamura, Masato
    Kotaka, Masahito
    Eto, Tetsuya
    Manaka, Dai
    Hasegawa, Junichi
    Takagane, Akinori
    Kato, Takeshi
    Munemoto, Yoshinori
    Nakamura, Fumitaka
    Bando, Hiroyuki
    Taniguchi, Hiroki
    Gamoh, Makio
    Shiozawa, Manabu
    Yamanaka, Takeharu
    Mizushima, Tsunekazu
    Sakamoto, Junichi
    Saji, Shigetoyo
    Ohtsu, Atsushi
    Mori, Masaki
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [27] Impact of tumor and node stages on the efficacy of adjuvant oxaliplatin-based chemotherapy in stage III colon cancer patients: an ACCENT pooled analysis
    Cohen, R.
    Raeisi, M.
    Chibaudel, B.
    Yothers, G.
    Goldberg, R. M.
    Bachet, J. -B
    Wolmark, N.
    Yoshino, T.
    Schmoll, H. -J
    Haller, D. G.
    Kerr, R.
    Lonardi, S.
    George, T. J.
    Shacham-Shmueli, E.
    Shi, Q.
    Andre, T.
    de Gramont, A.
    ESMO OPEN, 2025, 10 (03)
  • [28] Efficacy of oxaliplatin-based adjuvant chemotherapy in older patients with stage III colon cancer: An ACCENT/IDEA pooled analysis of 12 trials
    Gallois, C.
    Shi, Q.
    Meyers, J.
    Andre, T.
    Iveson, T. J.
    Sobrero, A. F.
    Alberts, S.
    de Gramont, A.
    Meyerhardt, J.
    Shields, A. F.
    Georges, T.
    Schmoll, H. J. E-V.
    Souglakos, I.
    Kerr, R.
    Lonardi, S.
    Yothers, G.
    Yoshino, T.
    Goldberg, R.
    Taieb, J.
    Papamichael, D.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S682 - S683
  • [29] ACHIEVE-2 trial: A randomized phase III trial investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with high-risk stage II colon cancer (CC)
    Yoshino, T.
    Yamanaka, T.
    Shiozawa, M.
    Manaka, D.
    Kotaka, M.
    Gamoh, M.
    Shiomi, A.
    Makiyama, A.
    Munemoto, Y.
    Rikiyama, T.
    Fukunaga, M.
    Ueki, T.
    Shitara, K.
    Shinkai, H.
    Tanida, N.
    Yamazaki, K.
    Sunami, E.
    Ohtsu, A.
    Maehara, Y.
    ANNALS OF ONCOLOGY, 2019, 30
  • [30] Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial
    Andre, Thierry
    Vernerey, Dewi
    Mineur, Laurent
    Bennouna, Jaafar
    Desrame, Jerome
    Faroux, Roger
    Fratte, Serge
    de Larauze, Marine Hug
    Paget-Bailly, Sophie
    Chibaudel, Benoist
    Bez, Jeremie
    Dauba, Jerome
    Louvet, Christophe
    Lepere, Celine
    Dupuis, Olivier
    Becouarn, Yves
    Mabro, May
    Egreteau, Joelle
    Bouche, Olivier
    Deplanque, Gael
    Ychou, Marc
    Galais, Marie Pierre
    Ghiringhelli, Francois
    Dourthe, Louis Marie
    Bachet, Jean-Baptiste
    Khalil, Ahmed
    Bonnetain, Franck
    de Gramont, Aimery
    Taieb, Julien
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15) : 1469 - +
12345